Clinical Trial Update: Topical Ketotifen 0.25% for Secondary Vestibulodynia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating topical ketotifen 0.25% for Provoked vestibulodynia and related dyspareunia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyspareunia
• Provoked Vestibulodynia
• Vulvodynia

Drugs mentioned

• Ketotifen (Ketotifen)

Snippet

Sponsor: Center for Vulvovaginal Disorders | Conditions: Provoked Vestibulodynia, Secondary Provoked Vestibulodynia | Phase 2 | Status: RECRUITING